- United States
- /
- Consumer Finance
- /
- NasdaqGM:DAVE
The Bull Case For Dave (DAVE) Could Change Following Insider Stock Sales And A Key Downgrade
Reviewed by Sasha Jovanovic
- In recent days, digital banking platform Dave has come under pressure after insiders, including the CEO and CFO, sold a combined US$91.3 million of stock over the past year and Weiss Ratings downgraded the company from a buy to a hold rating in late November 2025, prompting fresh scrutiny of management’s stance and business risks.
- What stands out is the contrast between these insider sales and downgrade on one hand, and separate third-party assessments highlighting strong revenue trends, improved credit performance, and supportive market conditions on the other, creating a more complex picture for investors assessing Dave’s outlook.
- We’ll now examine how the insider selling activity and resulting shift in sentiment could influence Dave’s previously positive investment narrative.
These 12 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
Dave Investment Narrative Recap
To own Dave today, you need to believe in the durability of its digital, fee-based banking model and the appeal of ExtraCash and subscription revenues, even as competition and regulation remain key threats. The recent insider selling and Weiss downgrade appear more sentiment driven than business driven, and do not directly change the near term focus on sustaining revenue growth while managing credit quality and regulatory risk.
The most relevant backdrop to this volatility is Dave’s latest quarterly result, where the company reported US$150.73 million in Q3 2025 revenue and US$92.07 million in net income, adding context to concerns about insider behavior. Those numbers, alongside third party commentary pointing to improved credit performance, frame the tension between strong recent execution and questions about how durable current monetization and engagement levels will be if regulatory or competitive pressures increase.
But against this strong recent scorecard, investors should still weigh the possibility that tighter rules on fee based, small dollar credit could...
Read the full narrative on Dave (it's free!)
Dave's narrative projects $702.2 million revenue and $193.0 million earnings by 2028.
Uncover how Dave's forecasts yield a $306.38 fair value, a 46% upside to its current price.
Exploring Other Perspectives
Four members of the Simply Wall St Community currently estimate Dave’s fair value between US$177 and US$320 per share, underscoring how far opinions can diverge. You should weigh those views against the risk that future regulation of small dollar, fee based credit products could directly affect Dave’s core ExtraCash economics and its ability to sustain recent margin strength.
Explore 4 other fair value estimates on Dave - why the stock might be worth 16% less than the current price!
Build Your Own Dave Narrative
Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.
- A great starting point for your Dave research is our analysis highlighting 3 key rewards that could impact your investment decision.
- Our free Dave research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Dave's overall financial health at a glance.
Want Some Alternatives?
Our top stock finds are flying under the radar-for now. Get in early:
- We've found 15 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
- The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 26 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
- AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About NasdaqGM:DAVE
Dave
Provides various financial products and services through its financial services platform in the United States.
Outstanding track record with excellent balance sheet.
Similar Companies
Market Insights
Weekly Picks

Crazy Undervalued 42 Baggers Silver Play (Active & Running Mine)

Fiducian: Compliance Clouds or Value Opportunity?
Willamette Valley Vineyards (WVVI): Not-So-Great Value
Recently Updated Narratives
Watch Pulse Seismic Outperform with 13.6% Revenue Growth in the Coming Years
Significantly undervalued gold explorer in Timmins, finally getting traction
Moderation and Stabilisation: HOLD: Fair Price based on a 4-year Cycle is $12.08
Popular Narratives

MicroVision will explode future revenue by 380.37% with a vision towards success

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026
